Navigation Links
Gene therapy study shows safety and statistically significant improvement in Parkinson's disease

time of surgery, while prior studies of AAV-mediated gene therapy show that gene expression gradually increases to a maximal level over a period of weeks.

“We are very encouraged by the results of this trial and its publication in such a prestigious journal,” said John Mordock, Neurologix President and Chief Executive Officer. “Since the inception of the company, we have been a leader in developing gene therapy for neurological disease, and we feel that rigorous peer-review and publication of the results from this first-ever trial is an important milestone for this entire field. These promising observations certainly warrant further, more definitive testing of Neurologix’s technology, and we anticipate beginning a larger Phase 2 study in Parkinson’s disease later this year. Moreover, the results also provide a solid foundation for the development of our other therapeutic programs, including epilepsy where we plan to initiate a Phase 1 gene therapy study this year.”

Study Design

The study included 12 patients with advanced Parkinson’s disease, with four patients in each of three dose-escalating cohorts. All procedures were performed under local anesthesia and all 12 patients were discharged from the hospital within 48 hours of the procedure. At one year, all 12 patients as a group demonstrated a clinical improvement of 25% in the Unified Parkinson’s disease Rating Scale (UPDRS) compared to baseline (p<0.005). Nine of the 12 patients showed an average of 37% and five of these patients had substantial improvement of between 40% and 65%. Clinical improvement also correlated well to metabolic changes in glucose utilization as measured by PET scan. The PET scan data revealed a significant improvement (p<0.001) in brain metabolism on the treated side of the brain compared to the untreated side. No adverse events related to the gene therapy procedure were reported throughout the duration of the 12-month study, or in the subsequent two
'"/>

Source:JKureczka@comcast.net


Page: 1 2 3 4

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
(Date:11/4/2014)... of Madagascar,s 101 species of lemurs are threatened with ... rainforests they call home. A new study by Rice ... on rainforest tree populations, which raises concerns about the ... rich biodiversity. , A large proportion of trees in ... in turn disperse the seeds of their fruit trees ...
(Date:11/3/2014)... Research and Markets has announced the ... Markets and Companies" to their offering. ... which have already started to play an important role in ... the old fashioned bone marrow transplants. Role of cells in ... become a part of medical practice. Stem cells ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... in cells normally perform only one job, but a new ... out how to recruit enzymes for other jobs to benefit ... have one biological function in a cell, but many are ... those at the beginning of a chemical reaction ...
... tropical South Atlantic Ocean can be used to accurately ... of miles away in northwestern India, a University of ... Colder-than-normal July sea surface temperatures in the tropical South ... malaria epidemics in the arid and semi-arid regions of ...
... has discovered mutations in two genes that lead to the ... known as Lou Gehrig,s disease, and related degenerative diseases. ... the abnormal build-up of the proteins inside cells. These proteins ... also been linked to cancer, including the Ewing sarcoma, the ...
Cached Biology News:Promiscuous enzymes may be recruited to aid industry, medical fields 2Early warning system provides 4-month forecast of malaria epidemics in northwest India 22 new genes linked to amyotrophic lateral sclerosis and related disorders 22 new genes linked to amyotrophic lateral sclerosis and related disorders 3
(Date:11/24/2014)... 24, 2014 Continental Clinical Solutions, ... into clinical trials at its mid-Atlantic late-phase research ... was created with the idea of closing patient ... role in medical advances," said Continental's CEO, ... to the immortal cell line of Henrietta Lacks, ...
(Date:11/24/2014)... 24, 2014 The new video, ... METTLER TOLEDO demonstrates how to reduce the number ... and sample panel design can be complicated, requiring ... protect against corrosion and deposition. Dedicated single and ... amount of panel space. Additionally, installing and maintaining ...
(Date:11/24/2014)... Senior Vice President, General Manager ... skills, business acumen Elsevier , a ... and services, congratulates Diane Bartoli , Senior Vice ... Elsevier Clinical Solutions, for being recognized in the 13 ... issue of Profiles in Diversity Journal ® ...
(Date:11/22/2014)... Two new educational webinars hosted by DrugDev ... research and how the pharmaceutical industry can make life easier ... Where Does the ALS Money Go? , Featuring guest speaker ... 1:30pm ET, Register to attend , This webinar ... Julianne Dorn Professor of Neurology at Massachusetts General Hospital at ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2
... PAREXEL International,Corporation (Nasdaq: PRXL ) announced ... Small-Cap Growth Stock Conference in New York, NY. ... will be making,a formal presentation on PAREXEL at ... A live webcast of this presentation will be ...
... G2 approved by leading European authority on natural/ ... CALGARY, Oct. 6 /PRNewswire-FirstCall/ - Botaneco Specialty ... (SemBioSys), today,announced that its second generation oleosome product, ... approved raw material, complying with,the standards for ecological ...
... Galenea Corp. and,Otsuka Pharmaceutical Co., Ltd. announced today ... collaboration. The two companies have,been working together since ... schizophrenia and other central nervous system (CNS),diseases. The ... of the initial,five-year alliance and brings the total ...
Cached Biology Technology:PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 3Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration 2Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration 3
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
Biology Products: